Solomon Woldu, M.D. Titles and Appointments Associate Professor School Medical School Department Urology You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Solomon Woldu, M.D., is an Associate Professor in the Department of Urology at UT Southwestern Medical Center. He specializes in urologic malignancies including bladder, kidney, prostate, and testicular cancers. Dr. Woldu grew up in the Dallas-Fort Worth area and holds a bachelor's degree in biology from Washington University in St. Louis. He earned his medical degree at Columbia University College of Physicians and Surgeons, and stayed in New York City for his general surgery internship and urology residency at Columbia University Medical Center. After his residency, he came back to Dallas to pursue a fellowship in oncology at UT Southwestern. The two-year Society of Urologic Oncology fellowship included both research and advanced clinical training in complex open and minimally invasive surgery. During this fellowship, he was the recipient of a National Institutes of Health training grant. His research interests are broad, and he has published over 100 peer-reviewed articles and multiple book chapters in urology. He regularly presents his research findings at national medical conferences and was voted "Teacher of the Year" by the urology trainees in 2022. Dr. Woldu maintains a busy clinical practice at UT Southwestern and sees patients in clinic at Moncrief Medical Center in Fort Worth and performs surgeries at Clements University Hospital in Dallas. He also serves as Chief of Urology at John Peter Smith hospital where he performs complex urologic oncology and reconstructive procedures. Dr. Woldu and his wife, Dr. Kristal Woldu live in Fort Worth, Texas with their 3 kids. He is active in the Fort Worth community and enjoys cycling, running, and running around after the kids. Education Medical School Columbia University College of Physicians and Surgeons (2010) Internship Columbia Presbyterian Medical Center (2011), General Surgery Residency Columbia Presbyterian Medical Center (2016), Urology Fellowship UT Southwestern Medical Center (2018), Urologic Oncology Research Interest Bladder Cancer, Prostate Cancer, Kidney Cancer, Testicular Cancer Publications Featured Publications Impact of timing of computed tomography staging and patient factors on the detection of 'true' cN+ bladder cancer. von Deimling M, Furrer M, Bianchi A, Pichler R, Maas M, Tully KH, Longoni M, Mertens LS, Taylor J, Del Giudice F, Li R, Gallioli A, Albisinni S, Crocetto F, Velev M, Afferi L, Mari A, Laukhtina E, Klemm J, Singla N, Fisch M, Spiess PE, Lotan Y, Moschini M, Black PC, Antonelli A, Kiss B, Shariat SF, Pradere B, BJU Int 2025 Jul Surgical Outcomes of Radical Nephrectomy and Inferior Vena Cava Thrombectomy Following Preoperative Systemic Immunotherapy: A Propensity Score Analysis. Khene ZE, Bhanvadia R, Tachibana I, Issa W, Graber W, Trevino I, Woldu SL, Gaston K, Zafar A, Hammers H, Cole S, Zhang T, Bensalah K, Lotan Y, Margulis V, Clin Genitourin Cancer 2025 Apr 23 2 102307 Understanding the hospital safety net: Hospital resource limitations impact prostate cancer treatment beyond socioeconomic disparities. Bhanvadia RR, Badia RR, Baky FJ, Tse JW, Lotan Y, Woldu SL, Margulis V, Can Urol Assoc J 2025 Mar Impact of baseline PD-L1 status in BCG naive nonmuscle invasive bladder cancer on outcomes and changes after BCG exposure. Gerald T, Woldu SL, Halstuch D, Ber Y, Lifshitz K, Cook G, Francis F, Margel D, Jia L, Lotan Y, Urol Oncol 2025 Feb Gemcitabine Versus Bacillus Calmette-Guérin for Intravesical Therapy in Treatment-Naïve Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer. Khene ZE, Bhanvadia R, Attia S, Ito W, Trevino I, Woldu SL, Margulis V, Lotan Y, J Urol 2025 Feb 101097JU0000000000004472 Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non-muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies. Annapureddy D, Taylor JI, Kamat AM, O'Donnell MA, Howard J, Tan WS, McElree IM, Davaro F, Yim K, Harrington S, Dyer E, Black AJ, Kanabur P, Roumiguié M, Lerner S, Black PC, Raman JD, Preston MA, Steinberg G, Huang W, Li R, Packiam VT, Woldu SL, Lotan Y, Eur Urol Focus 2025 Feb Durability of response of UGN-101: Longitudinal follow up of multicenter study. Woldu SL, Igel D, Johnson B, Murray KS, Miyagi H, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin MA, Heidenberg D, Humphreys M, Ghodoussipour S, Quek ML, O'Donnell M, Eisner BH, Matin SF, Feldman AS, Lotan Y, Urol Oncol 2025 Jan Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer. Taylor J, Kamat AM, Annapureddy D, Khene ZE, Howard J, Tan WS, McElree IM, Facundo D, Yim K, Harrington S, Dyer E, Black AJ, Kanabur P, Roumiguié M, Lerner S, Black PC, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam VT, Woldu SL, Lotan Y, O'Donnell MA, Eur Urol Oncol 2024 Dec Editorial Comment. Lotan Y, Woldu S, J Urol 2024 Dec 101097JU0000000000004347 Predicting Response to Intravesical BCG in High-Risk NMIBC Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center Cohort. Lotan Y, Krishna V, Abuzeid WM, Launer B, Chang SS, Krishna V, Shingi S, Gordetsky JB, Gerald T, Woldu S, Shkolyar E, Hayne D, Redfern A, Spalding L, Stewart C, Eyzaguirre E, Imtiaz S, Narayan VM, Packiam VT, O'Donnell MA, Li R, Baekelandt L, Joniau S, Zuiverloon T, Fernandez MI, Schultz M, Hensley PJ, Allison D, Taylor JA, Hamza A, Kamat A, Nimgaonkar V, Sonawane S, Miller DL, Watson D, Vrabac D, Joshi A, Shah JB, Williams SB, J Urol 2024 Oct 101097JU0000000000004278 Results 1-10 of 20 1 2 Next Last Honors & Awards Resident Teacher of the Year (2022) NIH T32 Grant (2016-2018) Professional Associations/Affiliations American Board of Urology (2020) American Urological Association (2006) International Bladder Cancer Network (2022) Society of Urologic Oncology (2016)
